Trastuzumab emtansine: a game changer in HER2-positive early breast cancer.
Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably the greatest progress in the management of this aggressive form of breast cancer since the adjuvant trastuzumab pivotal trials. This article addresses the rationale behind the conception of the KATHERINE trial, T-DM1's structure and pharmacokinetics data, clinical efficacy data of the KATHERINE trial and of other EBC trials with T-DM1, safety aspects, implications of the KATHERINE trial results to clinical practice and future perspectives in the management of HER2-positive EBC.
['S Mano|Max|M|https://orcid.org/0000-0001-5666-5261']
D000080044:Ado-Trastuzumab Emtansine D000074322:Antineoplastic Agents, Immunological D000971:Antineoplastic Combined Chemotherapy Protocols D014408:Biomarkers, Tumor D001943:Breast Neoplasms D002986:Clinical Trials as Topic D003131:Combined Modality Therapy D005260:Female D006801:Humans D020360:Neoadjuvant Therapy D018719:Receptor, ErbB-2 D016896:Treatment Outcome
trastuzumab trastuzumab emtansine early breast cancer T-DM1 pathological complete response